GSK Plunges Into Patches, a Technology With a Troubled History

Last Updated Dec 17, 2009 6:42 AM EST

GlaxoSmithKline (GSK) might want to proceed carefully with its €117 million investment in Intercell, maker of vaccine patches. Patches have a lousy history as a reliable delivery method for some medicines.

To be clear: There's no evidence that there is anything wrong with Intercell's products.

However, other companies have tried needle- and pill-free medicine delivery systems in the form of patches in the past and been burned, including Johnson & Johnson (JNJ), Watson (WPI), Shire (SHPGY) and Noven (NOVN).

J&J quietly stopped actively marketing its Ortho Evra birth control patch after the product delivered unexpectedly large doses of estrogen, causing fatal blood clots.

Watson's fentanyl pain control patch has been recalled at least six times. And Shire and Noven collaborate on the Daytrana ADHD patch, which has been recalled eight times.

GSK and Intercell said they would explore using patches for other vaccines in GSK's portfolio. GSK might want to make sure the product does what it says on the box before rolling it out through all available franchises.

Comments

CBSN Live

pop-out
Live Video

Market Data

Watch CBSN Live

Watch CBS News anytime, anywhere with the new 24/7 digital news network. Stream CBSN live or on demand for FREE on your TV, computer, tablet, or smartphone.

Market News

Stock Watchlist